Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cardiff
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cardiff, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca24 Hoffmann-La Roche10 Novartis Pharmaceuticals10 Merck Sharp & Dohme LLC9 Janssen Research & Development, LLC8
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Cardiff

240 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Birmingham, London, Glasgow, Cardiff, Manchester
2027-11-23
Not yet open
Novonesis
Not applicable
300
Cardiff
2027-01
Not yet open
Novo Nordisk A/S
Phase 3
84
Birmingham, Cardiff, London, Oxford, Sheffield
2026-10-09
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
Aberdeen, Cardiff, Glasgow, Leeds, London
2026-09-30
Recruiting
Sanofi
Phase 2
8,000
Cardiff, Bournemouth, Dorchester, London, Portsmouth, Blackpool, Witney, West Kirby
2026-09-09
Recruiting
AstraZeneca
Phase 3
2,800
Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea
2026-09-01
Not yet open
Novonesis
Not applicable
150
Cardiff
2026-09
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
2026-08-28
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Ashton-under-Lyne, Basildon, Belfast, Birmingham, Brighton, Bristol, Cardiff, Clydebank
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Aberdeen, Cardiff, Corby, Coventry, Dundee, Glasgow, Leicester, Liverpool
2026-08-21
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Recruiting
Prilenia
Phase 3
400
Aberdeen, Birmingham, Cardiff, Liverpool, Newcastle upon Tyne
2026-07-01
Recruiting
Kite, A Gilead Company
Phase 3
550
Cardiff, London, Newcastle upon Tyne
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 3
138
London, Cardiff, Oxford
2026-05-15
Recruiting
Sarepta Therapeutics, Inc.
Phase 1
32
Cardiff
2026-05-12
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
Portal Therapeutics, Inc.
Observational
50
Cardiff, Dundee, London, Manchester
2026-04-30
Recruiting
Hoffmann-La Roche
Phase 3
360
London, Cardiff
2026-04-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton
2026-04-09
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Recruiting
Bristol-Myers Squibb
Phase 3
850
Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Hoffmann-La Roche
Phase 2
100
Sutton, Cardiff
2026-03-11
Recruiting
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Recruiting
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Cottingham, Cardiff, London, Manchester
2026-02-26
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Recruiting
Takeda
Phase 3
183
Exeter, Colcester, Gloucester, Cardiff, Milton Keynes, Stafford
2026-01-14
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Active, closed
Taiho Oncology, Inc.
Phase 3
360
Manchester, Nottingham, Torquay, Cardiff
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton
2025-12-19
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Cardiff, London, Manchester, Sheffield
2025-12-11
Recruiting
AstraZeneca
Phase 2
230
Birmingham, Cambridge, Cardiff, Newcastle
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
London, Cardiff, Nottingham
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton
2025-12-09
Recruiting
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Recruiting
Boehringer Ingelheim
Phase 3
670
Cardiff, Leicester, Manchester, Sutton, Torquay
2025-11-07
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Recruiting
A Study With CIT-013 in HS Patients
NCT06993233Hidradenitis Suppurativa (HS)
DrugsCIT-013 medium·CIT-013
Citryll BV
Phase 2
96
Cardiff, Chester, London
2025-10-31
Recruiting
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Cardiff, Glasgow, Manchester
2025-10-20
Recruiting
Novo Nordisk A/S
Phase 3
1,280
London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool
2025-10-02
Recruiting
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
Recruiting
Pfizer
Phase 3
1,000
Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Manchester
2025-09-28
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Ashburton, Belfast, Bellshill, Birmingham, Bristol, Bury St Edmunds, Cambridge, Cardiff
2025-09-22
Recruiting
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Guildford, Cambridge, Cardiff, London, Southampton
2025-08-28
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Nottingham, Swindon, Truro
2025-08-26
Recruiting
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
AstraZeneca
Phase 3
250
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
CSL Behring
Observational
200
Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds
2025-07-21
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Birmingham, London, Oxford, Coventry, Cardiff, Manchester
2025-07-16
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bellshill, Birmingham, Cardiff, London, Manchester
2025-07-02
Recruiting
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Recruiting
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Recruiting
Nova Laboratories Limited
Observational
180
Basildon, Cardiff, London, Manchester, Oxford
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland
2025-06-09
Recruiting
AstraZeneca
Phase 3
15,100
Birmingham, Bournemouth, Bridgend, Bristol, Calow, Cambridge, Cardiff, Chippenham
2025-06-04
Active, closed
Incyte Corporation
Phase 3
9
Cardiff, Glasgow, Leeds, Leicester, London
2025-06-04
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Birmingham, Newcastle upon Tyne, Cardiff, Sutton
2025-05-26
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Cottingham, Bristol, Cardiff, Coventry, Dundee, Glasgow, London, Manchester
2025-05-22
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Birmingham, Cardiff, London, Manchester
2025-05-21
Recruiting
Epax Norway AS
Not applicable
90
Cardiff
2025-04-30
Recruiting
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
Recruiting
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
Accession Therapeutics Limited
Phase 1/2
72
Glasgow, Cardiff, Leeds, Oxford
2025-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Leeds, Bristol, Cardiff, London, Southampton
2025-03-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Active, closed
Hoffmann-La Roche
Phase 4
274
Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton
2025-03-14
Recruiting
AbbVie
Phase 1/2
252
Leicester, Cardiff
2025-03-06
Recruiting
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Recruiting
BioNTech SE
Phase 2
60
Cardiff, Leeds, London, Manchester
2025-03-03
Recruiting
Daiichi Sankyo
Phase 3
726
Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester
2025-02-27
By invitation
Longboard Pharmaceuticals
Phase 3
324
Cardiff, Newcastle upon Tyne, Glasgow, London
2025-02-12
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Basingstoke, Tooting, Whitechapel, Birmingham, Cardiff, Leeds, Liverpool, London
2025-02-06
Recruiting
NovoCure GmbH
Phase 3
741
London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Basildon, Bath, Brighton, Cardiff, Chelsea, Cottingham, Glasgow, Liverpool
2025-01-07
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Recruiting
PepGen Inc
Phase 2
24
Salford, London, Cardiff, Newcastle upon Tyne
2024-12-10
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Bellshill, Birmingham, Cardiff, Hexham, London, Manchester
2024-12-03
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
50
Cardiff, Leeds, Liverpool, London, Southampton
2024-11-21
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London
2024-11-11
Recruiting
Alnylam Pharmaceuticals
Phase 1
66
Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth
2024-10-14
Active, closed
Incyte Corporation
Phase 2
130
Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2024-10-11
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
Cardiff, Plymouth, Wakefield
2024-10-03
Active, closed
Merus B.V.
Phase 3
699
Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton
2024-09-25
Recruiting
AbbVie
Phase 2
590
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Recruiting
Bayer
Phase 3
555
Torquay, Belfast, Guildford, Cardiff
2024-08-28
Active, closed
Kite, A Gilead Company
Phase 3
452
Bristol, Cardiff, Leeds, London, Newcastle
2024-08-23
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
DrugPelabresib
Novartis Pharmaceuticals
Phase 3
50
Cardiff, Glasgow, London
2024-08-13
Active, closed
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
Active, closed
GlaxoSmithKline
Phase 3
10,212
Orpington, Bellshill, Metropolitan Borough of Wirral, Witney, Bradford on Avon, Belfast, Birmingham, Cardiff
2024-08-01
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne
2024-07-30
Recruiting
Arbutus Biopharma Corporation
Observational
50
Cardiff, London
2024-07-11
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Active, closed
Merus B.V.
Phase 3
621
Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne
2024-06-25
Active, closed
AskBio Inc
Phase 2
127
Bristol, Cardiff
2024-06-11
Recruiting
X4 Pharmaceuticals
Phase 3
176
Cardiff, London
2024-06-06
Recruiting
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
NCT06372717Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse
Apollo Therapeutics Ltd
Phase 1
100
Cardiff, Glasgow, London
2024-06-04
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne
2024-05-13
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton
2024-04-01
Active, closed
Gilead Sciences
Phase 2
228
Bristol, Bury, Cambridge, Cardiff, London, North Shields
2024-03-27
Recruiting
AstraZeneca
Phase 3
5,250
Bicester, Bollington, Bradford, Cardiff, Chesterfield, Corby, Cottingham, Fowey
2024-02-21
Recruiting
Amicus Therapeutics
Observational
500
Birmingham, Cambridge, Cardiff, London, Manchester, Salford
2024-02-16
Active, closed
Sanofi
Phase 3
260
Cardiff, London, Leeds, Manchester, Newcastle upon Tyne
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
100
Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2024-01-16
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Birmingham, Cardiff, Glasgow, Hexham, London, Manchester
2024-01-11
Active, closed
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Recruiting
Intellia Therapeutics
Phase 3
1,200
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
2023-12-13
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Active, closed
AstraZeneca
Phase 3
1,835
Cardiff, Dundee, Glasgow, London, York
2023-11-07
Recruiting
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
MaaT Pharma
Phase 2
387
Cardiff
2023-10-31
Active, closed
AskBio Inc
Phase 2
150
Manchester, Leeds, Cardiff, Glasgow, London
2023-10-20
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry
2023-09-11
Recruiting
Biotest
Phase 3
590
Plymouth, London, Glasgow, Guildford, Cardiff
2023-09-09
Recruiting
AviadoBio Ltd
Phase 1/2
18
Cambridge, Cardiff, London
2023-08-30
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
By invitation
Vertex Pharmaceuticals Incorporated
Phase 3
174
Cardiff, London
2023-08-11
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Cambridge, London, Bellshill, Bradford, Cardiff, Chesterfield, Chorley, Cottingham
2023-06-28
Active, closed
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
290
Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York
2023-06-13
Recruiting
Takeda
Phase 3
240
London, Cardiff, Birmingham, Manchester
2023-05-16
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Cardiff, London, Manchester
2023-05-08
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Recruiting
Eupraxia Pharmaceuticals Inc.
Phase 1/2
117
Norwich, Cardiff, Liverpool, London
2023-03-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Bristol, Birmingham, Liverpool, London, Cardiff, Reading
2023-02-17
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Cardiff, Wakefield, London, Oxford, Salford
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Belfast, Cardiff, London, Sheffield
2023-02-13
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Cottingham, Bellshill, Birmingham, Cardiff, Chesterfield, Chorley, Edinburgh, Hexham
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Cardiff
2022-12-09
Active, closed
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Bellshill, Edgbaston, Manchester, Cardiff, Hampstead, Liverpool, London
2022-11-30
Active, closed
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence
NCT05424484Incisional Hernia, Incisional Hernia of Midline of Abdomen, Midline Laparotomy
Medtronic - MITG
Not applicable
123
Chester, Cardiff
2022-11-22
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Active, closed
QBiotics Group Limited
Phase 2
15
Cardiff, Stevenage, Bebington, London
2022-11-03
Recruiting
AstraZeneca
Observational
287
Aylesbury, Bath, Birmingham, Bournemouth, Cardiff, Cornwall, Dartford, Derby
2022-10-17
Recruiting
EMD Serono Research & Development Institute, Inc.
Observational
700
Torquay, Huddersfield, Bedford, Birmingham, Bournemouth, Cardiff, Chelsea, Harrow
2022-10-04
Recruiting
Bristol-Myers Squibb
Observational
1,700
London, Manchester, Liverpool, Birmingham, Leeds, Cardiff
2022-08-16
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
210
Cardiff, London
2022-06-21
Recruiting
BioNTech SE
Phase 1
320
Cambridge, Cardiff, Liverpool, London, Newcastle upon Tyne
2022-06-17
Recruiting
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
Scancell Ltd
Phase 1/2
168
Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston
2022-04-07
Active, closed
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Recruiting
Takeda
Phase 3
120
London, Cardiff, Birmingham, Manchester
2022-02-10
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Penzance, Belfast, Birmingham, Blackpool, Cardiff, Durham, Enfield, Fowey
2022-02-07
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle
2022-01-13
Active, closed
Boston Scientific Corporation
Not applicable
500
Guildford, Cardiff, Belfast, Bristol, London, Norwich, Plymouth
2021-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Recruiting
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Cardiff, Birmingham, London, Oxford, Plymouth
2021-11-30
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Cardiff, Edinburgh, London, Manchester
2021-11-17
Recruiting
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Recruiting
AstraZeneca
Phase 1/2
460
Cambridge, Cardiff, London
2021-10-18
Active, closed
UniQure Biopharma B.V.
Phase 1/2
14
Cardiff, London
2021-10-07
Recruiting
Pfizer
Phase 3
893
Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester
2021-10-04
Active, closed
Boston Scientific Corporation
Phase 4
544
Cardiff, London, Middlesex
2021-08-02
Active, closed
GlaxoSmithKline
Phase 3
40
Bath, Brighton, Cardiff, Coventry, Edinburgh, Leeds, London, Maidstone
2021-06-28
Recruiting
Penumbra Inc.
Observational
1,500
Brighton, Cardiff, London
2021-06-25
Active, closed
Merck Sharp & Dohme LLC
Phase 2
302
Glasgow, London-Camden, Cardiff, Coventry
2021-06-25
By invitation
Philips Clinical & Medical Affairs Global
Not applicable
3,212
Southampton, Cardiff, Bournemouth, London
2021-06-17
Active, closed
Daiichi Sankyo
Phase 3
490
Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester
2021-05-21
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
2021-05-19
Recruiting
Alnylam Pharmaceuticals
Observational
150
Cardiff, London
2021-04-26
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
BioNTech SE
Phase 2
327
Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester
2021-03-08
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Bristol, Cardiff, Glasgow, London
2021-03-04
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
5,000
Bath, Belfast, Cardiff, Chippenham, Craigavon, Darlington, Durham, Hampshire
2021-01-15
Active, closed
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Active, closed
Neurocrine Biosciences
Phase 3
182
Cardiff, London, Manchester, Salford
2020-12-16
Active, closed
GlaxoSmithKline
Phase 2/3
758
Cardiff, Edinburgh, London, Manchester
2020-12-08
Active, closed
Medicago
Phase 2/3
30,918
Aberdeen, Birmingham, Bournemouth, Cardiff, Chelmsford, Chorley, Derby, Harrow
2020-11-19
Active, closed
Bayer
Phase 3
402
Reading, Colchester, London, Bebington, Scunthorpe, Glasgow, Cardiff, Llanelli
2020-10-20
Recruiting
Epygenix
Phase 3
150
Cardiff, London, Sheffield
2020-09-15
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Recruiting
Eisai Inc.
Phase 1/2
182
Belfast, Glasgow, Manchester, Preston, London, Northwood, Cardiff, Sutton
2020-08-06
Active, closed
Genentech, Inc.
Phase 1
498
Birmingham, Cardiff, London, Manchester
2020-07-29
Active, closed
AstraZeneca
Phase 3
866
Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood
2020-07-24
Active, closed
Eli Lilly and Company
Phase 3
996
Cambridge, London, Cardiff
2020-06-22
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Liverpool, Birmingham, Cardiff, Glasgow, London
2020-03-12
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Cardiff, Sheffield, Glasgow, London
2020-02-11
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Bellshill, London, Londonderry, Hexham, Birmingham, Cardiff, Manchester
2019-11-26
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Truro, Plymouth, Sutton, Cardiff, London
2019-11-13
Active, closed
Bristol-Myers Squibb
Phase 3
790
Cardiff, Southampton
2019-10-28
Recruiting
GlaxoSmithKline
Phase 1/2
184
Birmingham, Cardiff, Glasgow Strathclyde, London, Manchester, Nottingham, Southampton
2019-10-25
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Newcastle upon Tyne, Cardiff, London
2019-10-03
Active, closed
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
DrugsDNA vaccine·ImmunoBody
Scancell Ltd
Phase 2
173
Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford
2019-08-19
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford
2019-08-12
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
Amgen
Phase 3
457
Cardiff, Glasgow, Liverpool, London, Manchester, Oxford
2019-07-19
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
By invitation
Novo Nordisk A/S
Observational
60
Aberdeen, Cardiff, Manchester, Sheffield
2019-04-01
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
Glasgow, Cardiff, London
2019-01-30
Active, closed
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260Hypertension, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
224
Basildon, Bournemouth, Canterbury, Cardiff, London, Newcastle upon Tyne
2018-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Bristol, Cardiff, London
2018-11-28
Active, closed
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Airdrie, Bristol, Cardiff, London, Oxford
2018-05-03
Active, closed
Orion Corporation, Orion Pharma
Phase 1/2
204
Bedlington, Cardiff, Glasgow, Liverpool, London, Manchester, Preston
2018-03-19
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
Janssen-Cilag International NV
Observational
135
Cardiff, London, Salford
2017-10-25
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness
2017-09-12
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Middlesex, Preston, Cardiff, London
2017-09-05
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
Cardiff, Leeds, London, Manchester
2017-05-22
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester
2016-12-22
Active, closed
Eisai Inc.
Phase 3
1,069
Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester
2016-10-13
Active, closed
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Active, closed
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
Active, closed
AstraZeneca
Phase 3
1,837
Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh
2014-04-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Blackburn, Cambridge, Cardiff, Dundee, Glasgow, Guildford, Leeds, London
2013-10-14
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Cardiff, Exeter, London, Manchester, Newcastle, Southampton, Wales
2013-03-18
Recruiting
Pompe Pregnancy Sub-Registry
NCT00567073Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Genzyme, a Sanofi Company
Observational
20
Cardiff
2007-06-18
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne
2004-09-15
Rows per page Showing 1–240 of 240
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/city/cardiff

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 240 of those studies with a site in Cardiff.

How many clinical trials are recruiting in Cardiff?

134 of the 240 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 5 have not yet opened recruitment, 93 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cardiff), 240 studies
PhaseStudiesRecruitingShare
Phase 31276452.9%
Phase 2371815.4%
Phase 1/2242210%
Observational21178.8%
Phase 2/31064.2%
Phase 1953.8%
Not applicable712.9%
Phase 4512.1%

Most active sponsors

Lead sponsors with the most studies (Cardiff)
Lead sponsorStudiesRecruiting
AstraZeneca2412
Hoffmann-La Roche106
Novartis Pharmaceuticals104
Merck Sharp & Dohme LLC96
BioNTech SE85
Janssen Research & Development, LLC84
Alnylam Pharmaceuticals64
Bristol-Myers Squibb65
AbbVie54
GlaxoSmithKline51
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.